Skip to content

Current Debt at other companies

Pfizer logo
PfizerPFE
$3.86B+3.0%
Amgen logo
AmgenAMGN
$5.44B+61.4%
Incyte logo
IncyteINCY
$4.41M-1.5%
Organon logo
OrganonOGN
$16M-20.0%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$1.7M+9.1%
Rhythm Pharmaceuticals, Inc. logo
Rhythm Pharmaceuticals, Inc.RYTM
$10.13M+537%

Other financials

Income statement

See full
Revenue$105.4M+60.1%
Gross profit$95.6M+67.7%
Operating income-$9.1M+62.9%
Net income-$11.3M+54.9%
EPS (diluted)-$0.09+55.0%

Balance sheet

See full
Cash & equivalents$35.1M-34.7%
Total debt$114.7M+3.5%
Total equity$189.6M+32.9%
Total assets$460.0M+33.7%

Cash flow

See full
Operating cash flow$2.2M+107%
CapEx--100%
Free cash flow$2.2M+107%

Valuation

See full
Market cap$3.28B+57.5%
Enterprise value$3.36B+57.0%
P/S7.9×-1.9×

Profitability

See full
Gross margin90.9%+2.5pp
Operating margin-12%-5.7pp
Net margin-13.9%-6.6pp
FCF margin-52.5%-21.9pp

Returns & leverage

See full
Return on equity-28.2%-13.0pp
Debt / equity0.6×-0.2×
Current ratio2.7×-0.9×

Where this comes from

Reported directly by Arcutis Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebtCurrent.

The official record: Arcutis Biotherapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arcutis Biotherapeutics, Inc.'s current debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arcutis Biotherapeutics, Inc.'s current debt?
Arcutis Biotherapeutics, Inc. (ARQT) reported current debt of $7.95M in Q1 2026.
What does current debt mean?
The portion of long-term debt maturing within the next 12 months, requiring refinancing or repayment from operating cash flows.